| Literature DB >> 33713668 |
Andreia Carona1, Joana Bicker1, Rui Silva1, Carla Fonseca1, Amílcar Falcão1, Ana Fortuna2.
Abstract
Epilepsy is one of the most common brain disorders, affecting more than 50 million people worldwide. Although its treatment is currently symptomatic, the last generation of anti-seizure drugs is characterized by better pharmacokinetic profiles, efficacy, tolerability and safety. Lacosamide is a third-generation anti-seizure drug that stands out due to its good efficacy and safety profile. It is used with effectiveness in the treatment of partial-onset seizures with or without secondary generalization, primary generalized tonic-clonic seizures and off-label in status epilepticus. Despite scarcely performed until today, therapeutic drug monitoring of lacosamide is proving to be advantageous by allowing the control of inter and intra-individual variability and promoting a successful personalized therapy, particularly in special populations. Herein, the pharmacology, pharmacokinetics, and clinical data of lacosamide were reviewed, giving special emphasis to the latest molecular investigations underlying its mechanism of action and therapeutic applications in pathologies besides epilepsy. In addition, the pharmacokinetic characteristics of lacosamide were updated, as well as current literature concerning the high pharmacokinetic variability observed in special patient populations and that must be considered during treatment individualization.Entities:
Keywords: Epilepsy; Individual variability; Lacosamide; Neuropathic pain; Pharmacokinetics; Pharmacology
Mesh:
Substances:
Year: 2021 PMID: 33713668 DOI: 10.1016/j.lfs.2021.119342
Source DB: PubMed Journal: Life Sci ISSN: 0024-3205 Impact factor: 5.037